Safety Profile · Adverse Event Reference
Safety & Adverse Effects
Balanced reference on the known safety profile, contraindications, drug interactions, and regulatory context of bremelanotide. Neutral tone. No dramatization.
Common Adverse Effects
Reported in Phase III RECONNECT trials
Nausea (~40% of subjects; most common)
Transient facial flushing
Hyperpigmentation at injection site
Headache
Transient blood pressure elevation
Contraindications (FDA Label)
Per approved prescribing information
Cardiovascular disease history
Uncontrolled hypertension
Concurrent organic nitrate use
High cardiovascular event risk baseline
Response Variability Factors
Inter-individual pharmacological variation
Individual MC4R expression and density
Subcutaneous tissue perfusion rate
Metabolic clearance rate
Psychological state at administration
Comorbid neuroendocrine conditions
Regulatory Status by Jurisdiction
As of 2024 regulatory data
United States: FDA-approved (Vyleesi® — HSDD, premenopausal women)
European Union: Not approved
Canada, Australia: Investigational status
Most other jurisdictions: Unregulated research compound
Professional Oversight Required
Bremelanotide is a pharmacologically active compound with an established adverse event profile. Its use outside supervised clinical settings carries meaningful risk. This reference does not constitute medical guidance. Consultation with a licensed healthcare provider is required for any clinical application.